You are viewing: Australia Cancer Biomarkers Market analysis
Part of: Cancer Biomarkers Market (Global)

The Australia Cancer Biomarkers Market was valued at $285.2 Million in 2026 and projected to reach to $499.4 Million by 2031, representing a compound annual growth rate of 9.8%. Australia's cancer biomarkers market is positioned for sustained expansion through 2031, supported by the country's advanced healthcare infrastructure and commitment to genomic medicine.

Australia Cancer Biomarkers Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Australia Cancer Biomarkers Market Trends and Insights

  • This 9.8% compound annual growth rate reflects Australia's advancing healthcare infrastructure, increasing cancer prevalence, and rising adoption of precision medicine diagnostics.
  • Australia's investment in genomic research and pathology innovation is driving demand for biomarker-based testing across oncology centers and diagnostic laboratories. The Australian market benefits from strong regulatory frameworks, high healthcare spending, and a population with increasing awareness of early cancer detection.
  • Australia's healthcare system prioritizes personalized treatment approaches, positioning biomarkers as critical tools for treatment selection and patient stratification.
  • Between 2026 and 2031, Australia is expected to see accelerated adoption of liquid biopsy technologies, immunoassays, and molecular profiling platforms across both public and private healthcare sectors. Australia's competitive landscape includes both multinational diagnostics companies and emerging local biotech firms developing innovative biomarker solutions.
  • Government support for cancer research and Medicare reimbursement policies are key enablers of market expansion in Australia..

Key Market Statistics

  • CAGR (2026-2031) 9.8% CAGR
  • Market Size, 2026 ~USD 285.2 Million
  • Forecast, 2031 ~USD 499.4 Million
  • Country Australia

Australia Cancer Biomarkers Market Overview

Market Valuation Growth :

Australia's cancer biomarkers market is valued at USD 285.2 million in 2026, with strong projection to reach USD 499.4 million by 2031, representing a 9.8% CAGR driven by healthcare modernization and precision oncology adoption.

Healthcare Infrastructure Advancement :

Australia's robust healthcare system and investment in genomic research facilities are accelerating the integration of advanced biomarker testing across major cancer centers and diagnostic laboratories nationwide.

Rising Cancer Prevalence :

Increasing cancer incidence rates across Australia are driving demand for early detection and personalized treatment strategies, positioning biomarkers as critical tools in oncology care pathways.

Precision Medicine Adoption :

Australian healthcare providers are increasingly embracing precision medicine diagnostics, with growing pathology innovation and genomic sequencing capabilities supporting targeted cancer treatment protocols.

Australia Cancer Biomarkers Market Dynamics

  • The 9.8% CAGR reflects increasing adoption of precision oncology diagnostics across major Australian medical centers and pathology networks.
  • Rising cancer prevalence and government initiatives promoting personalized medicine are key growth catalysts. The market will benefit from continued investment in genomic research facilities, expanding laboratory capabilities, and growing clinician awareness of biomarker-driven treatment protocols.
  • Australian healthcare providers' focus on improving patient outcomes through early detection and targeted therapies will drive sustained demand for innovative cancer biomarker solutions through the forecast period..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    In Vitro Diagnostics

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Dna Microarrays
    • Assay Kits
    • Microarrays
    Top Companies
    • ROCHE HOLDINGS AG
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Abbott Laboratories
    • Biomerieux s.a.

      Key Takeaways

      • Australia's cancer biomarkers market is valued at USD 285.2 million in 2026 and will reach USD 499.4 million by 2031, representing a 9.8% CAGR.
      • Australia's healthcare system's emphasis on precision medicine and personalized oncology is driving biomarker adoption across diagnostic and treatment pathways.
      • Liquid biopsy and molecular profiling technologies are emerging as high-growth segments in Australia's cancer biomarkers market.
      • Australia's regulatory environment and Medicare reimbursement policies create favorable conditions for biomarker test commercialization and market expansion.

      Cancer Biomarkers Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment LUNG CANCER (Cancer Type)
      Forecast Period 2026–2031
      Growth Rate CAGR of 11.6% from 2026 to 2031
      Largest Segment OMICS TECHNOLOGIES (Profiling Technology)
      Market Size Base Year (Billions) ~USD 28.2 (2026)
      Revenue Forecast (Billions) ~USD 48.82 (2031)
      Segments Covered Profiling Technology, Type, Cancer Type, Products

      Australia Cancer Biomarkers Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Profiling Technology

      • Imaging Technologies
      • Omics Technologies

      By Type

      • 2D Gel Electrophoresis
      • Antibodies
      • Biopsy Instruments
      • Computed Tomography (Ct)
      • Genomics
      • Imaging Instruments
      • Immunoassay
      • In-Situ Hybridization (Ish)
      • Kits And Reagents
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mass Spectrometry
      • Next Generation Sequencing
      • Other Omics Technologies
      • Other Proteomics Technologies
      • Pathology-Based Instrument
      • Polymerase Chain Reaction
      • Positron Emission Tomography (Pet)
      • Probes
      • Protein Microarray
      • Proteomics
      • Ultrasound Imaging

      By Cancer Type

      • Bladder Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Kidney Cancer
      • Leukemia
      • Lung Cancer
      • Melanoma
      • Non-Hodgkin'S Lymphoma
      • Other Cancer Types
      • Prostate Cancer
      • Thyroid Cancer

      By Products

      • Bioinformatics Software
      • Consumables
      • Instruments

      AUSTRALIA: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032

      Segment20242025202620272029203020312032CAGR (%)
      BIOPHARMACEUTICAL COMPANIES & CROS82.288.195.8104.5125.8139.2155172.810.3
      DIAGNOSTIC LABORATORIES194.4205.8220.8237.8278.9304.6334.7368.18.9
      OTHER END USERS15.215.516.116.818.419.420.621.95.2
      RESEARCH AND ACADEMIC INSTITUTES45.748.752.757.268.275.183.292.29.8
      TOTAL337.4358.1385.4416.2491.3538.3593.56559.2

      Target Audience

      • In Vitro Diagnostics (IVD) Manufacturers : Biomarker test developers and diagnostic companies need Australia-specific market data to assess market potential, identify unmet clinical needs, and develop localized commercialization strategies for the growing precision oncology segment.
      • Pharmaceutical & Biotechnology Companies : Drug developers require insights into Australian biomarker adoption patterns and companion diagnostic requirements to support clinical trial recruitment, regulatory submissions, and targeted therapy commercialization.
      • Pathology & Laboratory Networks : Australian pathology providers and diagnostic laboratories need market intelligence to guide investment in genomic testing infrastructure, staff training, and service expansion to meet growing demand for cancer biomarker testing.
      • Healthcare Investors & Private Equity : Investment firms evaluating opportunities in Australian healthcare diagnostics require detailed market sizing, growth forecasts, and competitive analysis to make informed investment decisions in cancer biomarker companies and platforms.
      • Hospital & Cancer Center Administrators : Healthcare facility leaders need market data on biomarker testing adoption, clinical outcomes, and reimbursement models to justify capital investments in precision oncology programs and diagnostic capabilities.

      Key Companies in the Australia Cancer Biomarkers Market

      CompanyHQOwnershipStrongest segments
      NANOSTRING TECHNOLOGIES, INCUnited States
      CELL SIGNALING TECHNOLOGY, INC.United States
      TRANSGENOMIC, INC.United States
      SANOFISpain
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging-based biomarker systems and software,In-vitro diagnostics instruments and consumables,Varian oncology platforms and services,
      BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyInstruments (flow cytometers, analyzers, automation),Consumables & reagents (antibodies, kits, collection products, media),
      MYRIAD GENETICSUnited StatesPublic CompanyHereditary cancer and germline oncology tests (e.g., MyRisk, BRACAnalysis CDx),Tumor-based prognostic and companion diagnostics (MyChoice CDx, Prolaris, EndoPredict, Precise Tumor),Other oncology-adjacent genomics and lab services within cancer workflows,
      SYSMEX CORPORATIONJapanPublic CompanyInstruments (hematology, coagulation, cell analysis platforms),Consumables (reagents, calibrators, controls, software-linked services),
      HOLOGIC, INC.United StatesPrivate CompanyBreast cancer imaging systems and software,Biopsy guidance systems and markers,Cytology and related consumables (ThinPrep),

      NANOSTRING TECHNOLOGIES, INC

      NanoString Technologies develops and commercializes molecular analysis platforms for gene expression profiling and genomic research.

      CELL SIGNALING TECHNOLOGY, INC.

      Cell Signaling Technology Inc. produces research antibodies, proteins, and assay kits for cell biology and life sciences research.

      TRANSGENOMIC, INC.

      Transgenomic Inc. provides genetic testing and molecular diagnostics solutions for disease detection and management.

      SANOFI

      Sanofi is a multinational pharmaceutical company developing and marketing medicines, vaccines, and diagnostic products.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a global medical technology company providing diagnostic imaging, laboratory diagnostics, and healthcare IT solutions.

      BECTON, DICKINSON AND COMPANY

      Becton, Dickinson and Company manufactures and distributes medical devices, laboratory equipment, and diagnostic systems.

      MYRIAD GENETICS

      Myriad Genetics is a molecular diagnostics company providing genetic testing and precision medicine solutions for cancer and other diseases.

      SYSMEX CORPORATION

      Sysmex Corporation manufactures and sells hematology, hemostasis, and clinical chemistry diagnostic systems and reagents.

      HOLOGIC, INC.

      Hologic Inc. develops and markets diagnostic and medical imaging systems, particularly for women's health and cancer detection.

      Reasons to Buy this Report

      • Market-Specific Growth Projections : Access detailed forecasts for Australia's cancer biomarkers market from 2026-2031, enabling accurate business planning and investment decisions tailored to the Australian healthcare landscape.
      • Competitive Landscape Intelligence : Understand key players, market consolidation trends, and competitive positioning specific to Australia's oncology diagnostics sector to identify partnership and expansion opportunities.
      • Regulatory & Reimbursement Insights : Gain comprehensive analysis of Australian regulatory frameworks, TGA approvals, and Medicare reimbursement pathways for cancer biomarker tests to navigate market entry and commercialization strategies.
      • Healthcare Provider Adoption Trends : Identify adoption rates across Australian hospitals, pathology networks, and cancer centers, revealing demand drivers and implementation barriers for biomarker-based diagnostics.
      • Strategic Market Segmentation : Analyze Australia's market by biomarker type, cancer indication, and end-user segment to pinpoint high-growth opportunities and tailor product development and marketing strategies.

      Frequently asked questions

      What is the current size of Australia's cancer biomarkers market?

      Australia's cancer biomarkers market was valued at USD 285.2 million in 2026 and is expected to grow to USD 499.4 million by 2031.

      What is the projected growth rate for Australia's cancer biomarkers market?

      Australia's cancer biomarkers market is projected to grow at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2031.

      Which biomarker technologies are driving growth in Australia?

      Liquid biopsy, immunoassays, molecular profiling, and genomic sequencing technologies are key drivers of growth in Australia's cancer biomarkers market.

      How does Australia's healthcare system support biomarker adoption?

      Australia's healthcare system supports biomarker adoption through Medicare reimbursement policies, strong regulatory frameworks, and investment in precision medicine research and infrastructure.

      What factors are contributing to market expansion in Australia?

      Rising cancer prevalence, increasing healthcare spending, growing awareness of early detection, government research support, and adoption of personalized treatment approaches are key growth factors in Australia.

      RESEARCH METHODOLOGY

      The objective of the study is to analyze key market dynamics, including drivers, opportunities, restraints, challenges, and key players' strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, the competitive landscape of the cancer biomarkers market will be analyzed, and market players will be evaluated on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.
      The four steps involved in estimating the market size are

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess prospects.

      The following is a breakdown of the primary respondents

      Cancer Biomarkers Market Size, and Share

      Note 1: Others include sales, marketing, and product managers.
      Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

      COMPANY NAME

      DESIGNATION

      Thermo Fisher (US)

      Sales Manager

      F. Hoffmann-La Roche AG (Switzerland)

      Product Manager

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total market size of cancer biomarkers. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry have been identified through extensive secondary research
      • The revenues generated by leading players operating in the cancer biomarkers market have been determined through primary and secondary research
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

      Cancer Biomarkers Market : Top-Down and Bottom-Up Approach

      Cancer Biomarkers Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the overall market size using the process described above, the total market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Cancer biomarkers are biological molecules produced by the body or a tumor in a person with cancer. Cancer biomarker testing helps differentiate alterations in the tumor. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. It can also be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. Biomarkers can be DNA, RNA, proteins, or metabolomic profiles specific to the tumor. They enhance cancer detection and facilitate high-speed, noninvasive diagnosis using profiling technologies such as omics, imaging, immunoassays, and cytogenetics.

      Key Stakeholders

      • Product Manufacturers, Distributors, and Suppliers
      • Diagnostic Laboratories
      • Research Laboratories and CROs
      • Ambulatory Testing Centers
      • Contract Testing Laboratories
      • Academic Universities and Medical Research Centers
      • Research and Development (R&D) Centers

      Report Objectives

      • To define, segment, and forecast the cancer biomarkers market by profiling technology, cancer type, product, application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to six regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries
      • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To benchmark players within the market using the proprietary company evaluation matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
      • To study the impact of AI on the market, along with the macroeconomic outlook for each region

      Available customizations:

      MarketsandMarkets offers the following customizations for this market report.

      Product Analysis

      • Product matrix, which provides a detailed comparison of the product portfolio of each company in the cancer biomarkers market

      Country Information

      • Additional country-level analysis of the cancer biomarkers market

      Company Profiles

      • Additional five company profiles of players operating in the cancer biomarkers market.

      Get the Full Cancer Biomarkers Market Report

      Full forecast, segment splits, and company analysis for all Cancer Biomarkers Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status